Amphotericin B Lipid Complex (Abelcet®) in the treatment of invasive mycoses: The North American experience

European Journal of Haematology, Supplement

Volumn 56, Issue 57, 1996, Pages 18-23

  Lister, J ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

amphotericin B Lipid Complex; clinical trials; invasive fungal infection; neutropenia; pharmacokinetics

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; LIPID; ANTIFUNGAL AGENT; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL;

ASPERGILLOSIS; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DOG; DYSPNEA; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MYCOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ARTICLE; DRUG COMBINATION; NORTH AMERICA;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DOGS; DRUG COMBINATIONS; MICE; MYCOSES; NORTH AMERICA; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RATS;

EID: 0029899877     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. WALSH TJ, LEE J, LECCIONES J, et al. Empirie therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991: 13: 496-503.
2. SABRA R, BRANCH RA. Amphotericin B nephrotoxicity. Drug Safety 1990: 5: 94-108.
3. MEUNIER F. Alternative modalities of administering amphotericin B: current issues. J Infect 1994: 28: 51-56.
4. JANOFF AS, BONI LT, POPESCU MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988: 85: 6122-6126.
5. MADDEN TD, JANOFF AS, CULLIS PR. Incorporation of amphotericin B into large unilamellar vesicles composed of phophatidylcholine and phosphatidylglycerol. Chem Phys Lipids 1990: 52: 189-198.
6. MILHAUD J, HARTMANN MA, BOLARD J. Interaction of the polyene antibiotic amphotericin B with model membranes: differences between small and large unilamellar vesicles. Biochimie 1989; 71: 49-56.
7. OLSEN SJ, SWERDEL MR, BLUE B, CLARK JM, BONNER DP. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991: 43: 831-835.
8. JANOFF AS, PERKINS WR, SALETAN SL, SWENSON CE. Amphotericin B Lipid Complex (ABLC®): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993: 3: 451-472.
9. GATES C, PINNEY RJ. Amphotericin B and its delivery by liposomal and lipid formulations. J Clin Pharm Ther 1993: 18: 147-153.
10. GRANT CW, HAMILTON KS, HAMILTON KD, BARBER KR. Physical biochemistry of a liposomal amphotericin B mixture used for patient treatment. Biochim Biophys Acta 1989: 984: 11-20.
11. ALLENDOERFER R, YATES RR, SUN SH, GRAYBILL JR. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992: 30: 377-384.
12. CLARK JM, WHITNEY RR, OLSEN SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991: 35: 615-620.
13. CLEMONS KV, STEVENS DA. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991: 35: 2144-2146.
14. CLEMONS KV, STEVENS DA. Efficacies of amphotericin B lipid complex and conventional amphotericin B suspension against murine coccidioidomycosis. Antimicrob Agents Chemother 1992: 30: 353-363.
15. MITSUTAKE K, KOHNO S, MIYAZAKI Y, et al. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 1994: 128: 13-17.
16. PERFECT JR, WRIGHT KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994: 33: 73-81.
17. The Liposome Company. Data on file, 1993.
18. LISTER J. Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy. Blood 1994: 84: 306a.
19. HIEMENZ JW, SEIBEL T, WALSH T. Safety and efficacy of amphotericin B lipid complex (ABLC®) in neutropenic patients with life-threatening mycoses. Ann Oncol 1994: 5(suppl 8): 202, abst P1017.